400 reports on adverse drug reactions associated with antineoplastic drugs

doi:10.19803/j.1672-8629.2022.05.14

Abstract

Abstract: Objective To analyze the characteristics and regularities of adverse drug reactions (ADR) induced by antineoplastic drugs and provide reference for clinical rational use of antineoplastic drugs. Methods Totally 400 reports about ADR caused by antineoplastic drugs between January 1, 2017 and August 31, 2019 were collected and retrospectively analyzed based on patients' gender, age, routes of administration, reaction grading, drug types and organs/systems involved in the ADR caused by antineoplastic drugs. Results Amon the 400 reports of ADR, 159 involved males (39.75%) and 241 involved females (60.25%). The percentage of patients aged 61 to 70 was the highest (30.25%). Breast cancer was the primary disease in 151 of these cases (37.75%). Most of the ADR occurred during intravenous dripping (336, 84.00%). New and severe ADR occurred in 28 cases (7.00%) and severe ADR in 88 cases (22.00%). The highest composition ratio was with cisplatin in 123 cases (23.16%), and the digestive system was most likely to be involved in ADR, with a total of 313 cases (43.78%). A total of 377 cases (94.25%) of ADR were cured and improved. Conclusion To monitor ADR in clinical use of antitumor drugs, clinicians should focus on special populations, key drugs and typical symptoms while treating ADR promptly and properly to ensure the safety of drug use.

Key words: antineoplastic agents, adverse drug reaction, safe medication

CLC Number:

R994.11

TAI Xinjuan, MA Hongfeng, LI Jun, MA Weixing, YAN Yawei. 400 reports on adverse drug reactions associated with antineoplastic drugs[J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 541-544.

References

[1] CHEN XQ, JIN YY, TANG G, et al.New Edited Materia Medica(新编药物学)[M]. 17 th Ed. Beijing: People's Medical Publishing House, 2011.
[2] WHO term set for adverse drug reactions. The system involved - organ code retrieval[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2009, 6(1): 63-64.
[3] XU WJ, GAO Y, YE ML, et al.Analysis of 346 adverse drug reactions reports associated with antineoplastic drugs in a tertiary class A hospital.[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2020, 17(2): 104-107.
[4] ZHENG RS, SUN KY, ZHANG SW, et al. Malignant tumor epidemiology in china, 2015[J]. Chinese Journal of Oncology(中华肿瘤杂志), 2019(1): 19-28.
[5] WANG YP, HU ZP, SA RN, et al.Incidence and mortality of cancer in Shaanxi cancer registries, 2015[J]. China Cancer(中国肿瘤), 2020, 29(5): 344-354.
[6] WU HW, BAI Y, LIU H, et al.Clinical analysis of 273 adverse drug reaction reports of antineoplastics in our hospital[J]. China Medical Herald(中国医药导报), 2017, 14(14): 126-130.
[7] MARKUS GALANSKI.Recent developments in the field of anticancer platinum complexes[J]. Recent Patents on Anti-Cancer Drug Discovery, 2006, 1(2): 285-295.
[8] YU P, YUE EL, XIAO CR, et al.A phase I clinical trial of dose escalation of lobaplatin in combination with fixeddose docetaxel for the treatment of human solid tumors that had progressed following chemotherapy[J]. Oncology Letters, 2015, 9(1): 67-74.
[9] WEI LY, QIU XC, ZHOU YL, et al.Analysis of 907 cases of adverse drug reactions induced by antineoplastic drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(4): 242-245.
[10] ZHANG N, WANG JG, LI JB, et al.Analysis of 304 cases of adverse reactions of antitumor drugs from spontaneous reporting[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2015, 24(2): 107-110.
[11] DOU F, CHEN Y, ZHANG W, et al.Analysis on adverse reactions induced by antineoplastic drugs in Xijing Hospital from 2015 to 2018[J]. Drugs & Clinic(现代药物与临床), 2019, 34(12): 3778-3781.
[12] NCCN clinical practice guidelines in oncology: antiemesis. Version1 2019 [EB/OL]. (2019-02-28)[2020-05-14]. http://www.nccn. org/ patients.
[13] WANG DZ, LIU BL. ZHANG SY, et al.Ridge regression study of restrainment of bone marrow in cancer patients with chemotherapy regiments and antitumor drugs[J]. Chinese Journal of Pharmaco-epidemiology(药物流行病学杂志), 2009, 18(3): 155-157.
[14] WANG D, REN JT, DONG D, et al.Trend analysis of ten-year annual reports on adverse drug reaction monitoring[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(5): 276-283.
[15] HANG JH, WANG SY, GUAN YP, et al.Application progress of population pharmacokenitics/pharmacodymanics modeling in clinical development of anti-cancer drugs[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2019, 35(22): 2930-2933, 2947.